Alliance Global Partners initiated coverage of Nano-X Imaging (NASDAQ:NNOX) with a “buy” rating and price target of $14.50. The stock closed at $7.66 on Sept. 7. “Nano-X’s novel digital X-ray source has the potential to...
Alliance Global Partners initiated coverage of Aspira Women’s Health (NASDAQ:AWH) with a “buy” rating and price target of $5.60. The stock closed at $2.76 on Aug. 21. Aspira Women’s Health’s proprietary...
Alliance Global Partners initiated coverage of UpHealth (NYSE:UPH) with a “buy” rating and price target of $4.30. The stock closed at $1.45 on June 8. UpHealth operates as a digital health services company in the...
Raymond James raised its price target for Profound Medical (NASDAQ:PROF) to $17 from $15 and reiterated a “strong buy” rating after the company said its application for full CPT-1 reimbursement for TULSA-PRO has been...
Alliance Global Partners initiated coverage of CollPlant Biotechnologies (NASDAQ:CLGN) with a “buy” rating and price target of $22.75. The stock closed at $11.80 on Feb. 16. CollPlant has developed a proprietary method...
Alliance Global Partners launched coverage of Hepion Pharmaceuticals (NASDAQ:HEPA) with a “buy” rating and price target of $4. Shares of Hepion closed at 73 cents on Jan. 31. Analyst James Molloy writes that his...
Alliance Global Partners dropped coverage of Vivere Medical (NASDAQ:VIVE) after its pivotal PURSUIT trial in stress urinary incontinence (SUI) in women did not meet its primary endpoint nor several secondary endpoints...
Alliance Global Partners initiated coverage of MeaTech 3D (NASDAQ:MITC) with a “buy” rating and $11 price target. The stock closed at $3.55 on July 15. MeaTech is a cellular agriculture firm focused on developing human...
Alliance Global Partners downgraded OpGen (NASDAQ:OPGN) to “neutral” and lowered its price target to 67 cents, citing the company’s cash needs. The stock closed at 61 cents on July 11. “We view the company’s...
Alliance Global Partners downgraded T2 Biosystems (NASDAQ:TTOO) to “neutral” from “buy” and reduced its price target to 14 cents from 65 cents, citing a fiscal second quarter preliminary revenue miss. The stock was...